{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"slu-pp-332","verification":{"valid":true,"entries":7,"head":"3ff096fde160703c4d04b249fdf292217bfa96fef4580ea4871142007c66ff24"},"count":7,"sources":[{"id":"s1","type":"pubmed","pmid":"36988910","external_id":"36988910","url":"https://pubmed.ncbi.nlm.nih.gov/36988910/","title":"Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity","quote":"Here, we report the identification of a synthetic ERR pan agonist, SLU-PP-332, that targets all three ERRs but has the highest potency for ERRα. Additionally, SLU-PP-332 has sufficient pharmacokinetic properties to be used as an in vivo chemical tool.","summary":"Billon et al., ACS Chem Biol 2023: the paper that introduced the compound. Its own description of what SLU-PP-332 is — a chemical tool with enough pharmacokinetics to survive an animal experiment, not a drug candidate. That framing is the single most important fact about it and it comes from the people who made it.","author":"Billon C, Sitaula S, Banerjee S, Welch R, Elgendy B, Hegazy L, Oh TG, Kazantzis M, Chatterjee A, Chrivia J, Hayes ME, Xu W, Hamilton A, Huss JM, Zhang L, Walker JK, Downes M, Evans RM, Burris TP","publisher":"ACS Chemical Biology","date":"2023","tag":"Discovery paper","accessed_at":"2026-08-05T09:39:20.709Z","prev":"genesis","hash":"fb67c9ddf6e5943cc5549a2fcdf31889f7775c5c12ba398a7505672d3fbc8d74"},{"id":"s2","type":"pubmed","pmid":"36988910","external_id":"36988910-fibres","url":"https://pubmed.ncbi.nlm.nih.gov/36988910/","title":"Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity","quote":"When administered to mice, SLU-PP-332 increased the type IIa oxidative skeletal muscle fibers and enhanced exercise capacity.","summary":"SLU-PP-332 in mice: type IIa oxidative fibres and exercise capacity. The core animal result. Type IIa fibres are the fatigue-resistant, mitochondria-rich intermediate type, and growing their share is one of the specific things endurance training does. The compound produced that shift in animals that had not trained.","author":"Billon C, et al.","publisher":"ACS Chemical Biology","date":"2023","tag":"Animal result","accessed_at":"2026-08-05T09:39:20.709Z","prev":"fb67c9ddf6e5943cc5549a2fcdf31889f7775c5c12ba398a7505672d3fbc8d74","hash":"780d416d0062f20d92145e696efa24aef55d184369d59dc162510dbf6a0a3820"},{"id":"s3","type":"pubmed","pmid":"36988910","external_id":"36988910-undruggable","url":"https://pubmed.ncbi.nlm.nih.gov/36988910/","title":"Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity","quote":"Three ERR subtypes exist (ERRα, β, and γ), and although ERRβ/γ agonists have been designed, there have been significant difficulties in designing compounds with ERRα agonist activity.","summary":"Why ERRα had resisted every previous attempt. The reason this compound is a real scientific result rather than another metabolic molecule. ERRα is the subtype that governs the muscle programme and it was the one nobody could hit. SLU-PP-332 hits all three with the highest potency at ERRα.","author":"Billon C, et al.","publisher":"ACS Chemical Biology","date":"2023","tag":"Mechanism","accessed_at":"2026-08-05T09:39:20.709Z","prev":"780d416d0062f20d92145e696efa24aef55d184369d59dc162510dbf6a0a3820","hash":"c24e86dd352b026364e7945a4dca10013648bf244f47ef76562f2c15c179c016"},{"id":"s4","type":"pubmed","pmid":"37739806","external_id":"37739806","url":"https://pubmed.ncbi.nlm.nih.gov/37739806/","title":"A Synthetic ERR Agonist Alleviates Metabolic Syndrome","quote":"SLU-PP-332 administration mimics exercise-induced benefits on whole-body metabolism in mice including increased energy expenditure and fatty acid oxidation. These effects were accompanied by decreased fat mass accumulation. Additionally, the ERR agonist effectively reduced obesity and improved insulin sensitivity in models of metabolic syndrome.","summary":"Billon et al., J Pharmacol Exp Ther 2024: diet-induced obese and ob/ob mice. This is the study behind every fat-loss figure quoted for this compound. Note what it says and does not say — every measurement is in mice.","author":"Billon C, Schoepke E, Avdagic A, Chatterjee A, Butler AA, Elgendy B, Walker JK, Burris TP","publisher":"Journal of Pharmacology and Experimental Therapeutics","date":"2024","tag":"Animal efficacy study","accessed_at":"2026-08-05T09:39:20.709Z","prev":"c24e86dd352b026364e7945a4dca10013648bf244f47ef76562f2c15c179c016","hash":"02b1250b48f992337a7cfb737cf16f2e0570eb6854abe8e8a33054ca06c1c905"},{"id":"s5","type":"pubmed","pmid":"37739806","external_id":"37739806-significance","url":"https://pubmed.ncbi.nlm.nih.gov/37739806/","title":"A Synthetic ERR Agonist Alleviates Metabolic Syndrome","quote":"An estrogen receptor-related orphan receptor agonist, SLU-PP-332, with exercise mimetic activity, holds promise as a therapeutic to treat metabolic diseases by decreasing fat mass in mouse models of obesity.","summary":"The authors’ own significance statement, with its qualifier intact. The qualifier \"in mouse models of obesity\" is in the authors’ own summary sentence. It is the part that gets dropped when the numbers are repeated.","author":"Billon C, et al.","publisher":"Journal of Pharmacology and Experimental Therapeutics","date":"2024","tag":"Authors’ conclusion","accessed_at":"2026-08-05T09:39:20.709Z","prev":"02b1250b48f992337a7cfb737cf16f2e0570eb6854abe8e8a33054ca06c1c905","hash":"bfdc8f44728884d333676e94fa79d6b368ca771806f4ca6c6fc5eec761f1caa8"},{"id":"s6","type":"pubmed","pmid":"37961903","external_id":"37961903","url":"https://pubmed.ncbi.nlm.nih.gov/37961903/","title":"Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function","quote":"Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function.","summary":"Xu, Billon et al., Circulation 2024. The most double-edged paper in the set. A failing heart loses the ability to burn fat efficiently, and restoring that is a real therapeutic idea — these agonists did it in animal models. It is also the clearest published statement that this compound acts on cardiac muscle, which is dense with both mitochondria and ERR. Nobody has published what it does to a structurally normal human heart over months.","author":"Xu W, Billon C, Li H, Wilderman A, Qi L, Graves A, et al.","publisher":"Circulation","date":"2024","tag":"Animal study, cardiac","accessed_at":"2026-08-05T09:39:20.709Z","prev":"bfdc8f44728884d333676e94fa79d6b368ca771806f4ca6c6fc5eec761f1caa8","hash":"88a1626f35827fc6af0065259691c537917add9ed19f2dee2ac1be19971d4282"},{"id":"s7","type":"pubmed","pmid":"37717940","external_id":"37717940","url":"https://pubmed.ncbi.nlm.nih.gov/37717940/","title":"Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney","quote":"Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney.","summary":"Wang et al., Am J Pathol 2023. A fourth organ, a fourth real effect, same pattern. The mechanism is systemic — which is the point of it and also the thing to be careful about. Exercise produces these adaptations gradually, locally, and in proportion to the work done. A drug has no such self-limiting quality.","author":"Wang XX, Myakala K, Libby AE, Krawczyk E, Panov J, Jones BA, et al.","publisher":"The American Journal of Pathology","date":"2023","tag":"Animal study, renal","accessed_at":"2026-08-05T09:39:20.709Z","prev":"88a1626f35827fc6af0065259691c537917add9ed19f2dee2ac1be19971d4282","hash":"3ff096fde160703c4d04b249fdf292217bfa96fef4580ea4871142007c66ff24"}]}